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Abstract 
Background: Plasmodium vivax is the causative agent of human malaria of large geographic distribution, with 35 
million cases annually. In Brazil, it is the most prevalent species, being responsible by around 70 % of the malaria cases.
Methods: A cross‑sectional study was performed in Manaus (Amazonas, Brazil), including 36 adult patients with 
primary malaria, 19 with recurrent malaria, and 20 endemic controls. The ex vivo phenotypic features of circulating 
leukocyte subsets (CD4+ T‑cells, CD8+ T‑cells, NK, NKT, B, B1 and Treg cells) as well as the plasmatic cytokine profile 
(IL‑2, IL‑4, IL‑6, IL‑10, TNF and IFN‑γ) were assessed, aiming at establishing patterns of immune response characteristic 
of primary malaria vs recurrent malaria as compared to endemic controls.
Results: The proportion of subjects with high levels of WBC was reduced in malaria patients as compared to the 
endemic control. Monocytes were diminished particularly in patients with primary malaria. The proportion of sub‑
jects with high levels of all lymphocyte subsets was decreased in all malaria groups, regardless their clinical status. 
Decreased proportion of subjects with high levels of CD4+ and CD8+ T‑cells was found especially in the group of 
patients with recurrent malaria. Data analysis indicated significant increase in the proportion of the subjects with high 
plasmatic cytokine levels in both malaria groups, characterizing a typical cytokine storm. Recurrent malaria patients 
displayed the highest plasmatic IL‑10 levels, that correlated directly with the CD4+/CD8+ T‑cells ratio and the number 
of malaria episodes.
Conclusion: The findings confirm that the infection by the P. vivax causes a decrease in peripheral blood lympho‑
cyte subsets, which is intensified in the cases of “recurrent malaria”. The unbalanced CD4+/CD8+ T‑cells ratio, as well 
as increased IL‑10 levels were correlated with the number of recurrent malaria episodes. These results suggest that 
the gradual remodelling of the immune response is dependent on the repeated exposure to the parasite, which 
involves a strict control of the immune response mediated by the CD4+/CD8+ T‑cell unbalance and exacerbated IL‑10 
secretion.
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Background
Plasmodium vivax is widely distributed around the 
world, with more than 2.5 billion subjects exposed to risk 
of infection. Plasmodium vivax malaria is highly preva-
lent in Latin America, Asian and some Pacific regions [1]. 
In the past, P. vivax was considered the causative agent 
of “benign malaria” and was associated with low lethal-
ity. However, after several reports of severe forms of P. 
vivax malaria, this assumption has been challenged [2, 3]. 
Recent studies have shown that vivax malaria can be 
associated with a spectrum of severe syndrome, with risk 
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of death similar to that observed for Plasmodium falcipa-
rum infection [4–9].
In Brazil, the Amazon region concentrates almost all 
cases of P. vivax infections registered countrywide, with 
more than 300 thousand cases per year [10]. Although 
the Amazon region has low transmission levels as com-
pared to other regions in sub-Saharan Africa, the most 
affected population in the Amazon Basin are adults and 
the incidence of complications has been already reported 
[11, 12].
The recurrence of P. vivax malaria is a phenomenon 
that commonly occurs within a few months after the 
treatment of primary infection. The recurrence is defined 
as the reappearance of asexual forms of the parasite in 
the blood, up to 6  months after post-therapeutic moni-
toring period [13]. Usually, relapse/recrudescence may 
also occur for different reasons such as resistance of the 
parasite to the chemotherapy used [14], therapeutic fail-
ure, non-adherence to the treatment [15] and reactiva-
tion of the hypnozoites [16]. Recurrence has been rather 
considered a new malaria episode occurring in endemic 
areas after effective therapeutic intervention [17].
Although the mechanisms underlying the recurrence of 
are still unknown, cases of “recurrent malaria” are usu-
ally associated with impaired clinical recovery and higher 
morbidity, worsening the socio-economic impact of the 
disease [18–20]. From the epidemiologic point of view, it 
is likely that the recurrence favors the maintenance and 
transmission of the parasite, considering the early and 
continual presence of sexual forms of the P. vivax [21].
Several evidences suggest that an exacerbated inflam-
matory response associated to a high parasitaemia is 
likely to aggravate the malaria symptoms [22–27]. The 
exacerbated activation of the host immune system, espe-
cially T-lymphocytes is the core factor to the severe 
malaria pathogenicity, related to the high and out of pro-
portion levels of the pro-inflammatory cytokines, which 
can be observed during the erythrocytic phase of the 
parasite life cycle [9, 28–30]. In general, the severity of 
the disease has been associated with high systemic levels 
of IFN-γ and TNF [31–33]. In the P. vivax malaria, the 
simultaneous increase of the TNF, IFN-γ and IL-10 has 
been correlated to disease progression towards a severe 
clinical outcome [9, 34, 35].
Counterbalancing the exacerbated inflammatory 
response that induces immunopathological mechanisms 
[28], the host immune response develops modulatory 
events, especially in the lymphocytic compartment [36–
40]. It stands out the role of the regulatory T-cells (Treg), 
which may act as an important key both to the homoeo-
static balance and to the control of the immunopathogen-
esis through the modulation of the excessive inflammatory 
response [41]. Treg cells are necessary to control the cellular 
immune response through a direct contact with the effec-
tor immune cells and by the production of regulatory 
cytokines including IL-10 and TGF-β [42–44]. Further-
more, anti-inflammatory cytokines, included as IL-10, have 
been found to regulate type 1 responses during infection 
during a secondary parasitic challenge in the best available 
mouse model for human severe malaria, demonstrating a 
regulatory role in the control of pathogenic responses [44].
Nevertheless little information regarding the immuno-
logical events underlying the recurrent malaria episodes 
are currently available. In the present study, the ex  vivo 
phenotypic features of circulating leukocyte subsets as 
well as the plasmatic cytokine profile were assessed, aim-
ing at establishing patterns of immune response charac-
teristic of recurrent malaria.
Methods
Study population
This was a cross-sectional study performed during 
10  months with malaria patients seeking for healthcare 
at the Ambulatory of the Fundação de Medicina Tropi-
cal Dr. Heitor Vieira Dourado (FMT-HVD), Manaus, 
Amazonas State, Brazil. The selection of malaria patients 
was performed by convenience, excluding individuals 
with chronic/degenerative diseases or pregnant women. 
Only those patients with positive microscopic diagno-
sis of P. vivax infection with parasitaemia higher than 
500  parasite/mm3 were included in the study. Two sets 
of patients were selected for this study: patients with 
“primary malaria” and “recurrent malaria”. The inclu-
sion criteria for cases of P. vivax “recurrent malaria” were 
defined as patients that presented new malaria infection 
within a six-month interval apart from the last episode. 
The occurrence of relapse/recrudescence episodes was 
minimized, since all patients with “recurrent malaria” 
underwent therapeutic regimens as recommended by 
the Brazilian Ministry of Health to P. vivax malaria 
(chloroquine for 3 days and primaquine for 7 or 14 days) 
[45–48], with strict follow-up after treatment to monitor 
therapeutic effectiveness, according to FMT-HVD guide-
lines for cure-monitoring. The periodic cure-monitoring 
consisted of microscopic examination of thin and thick 
blood smears during the first 2 months (2, 4, 7, 14, 21, 28, 
40 and 60 days) after the initiation of treatment. In cases 
of positive microscopic results after the maximum time 
limit specified above, but before 6  months, the patients 
should be classified as new cases or “recurrent malaria”. 
Using this criterion, 13 patients with presumed “recur-
rent malaria” were excluded, as they reported presented 
parasitaemia levels lower than 500 parasite/mm3.
Fifty-five patients with P. vivax mono-infection 
[49], age ranging from 16 to 70  years, 39 males and 16 
females, all presenting negative serology for dengue virus 
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infection, were selected to compose the malaria group. 
Upon clinical evaluation, malaria patients were catego-
rized into two subgroups referred as: “primary malaria” 
(n = 36) and “recurrent malaria” (n = 19).
Twenty healthy subjects, resident in the same geo-
graphic area was enrolled as the “endemic control” group, 
with age ranging 19–48 years, nine man and 11 women.
Ethical issues and blood sampling
This study was approved by the Ethics Committee and 
the Superior Council at FMT-HVD (CAEE process 
#0044.0.114.000-11). Each participant read and signed 
the written informed consent form. EDTA whole blood 
samples (5 mL) were collected from each participant. All 
patients were treated according to the recommendations 
provided by the Brazilian Ministry of Health.
Assessment of Plasmodium vivax mono‑infection status
Total genomic DNA was extracted from EDTA whole 
blood samples, using the gDNA Blood kit (Invitrogen™, 
Carlsbad, CA, USA), following the instructions provided 
by the manufacturer. Plasmodium vivax mono-infection 
status was confirmed by Nested PCR, in the presence 
of specific oligonucleotides for P. vivax, P. falciparum 
and Plasmodium malariae, according to the protocol 
described by Snounou and Singh [50].
Monoclonal antibody panel for immunophenotypic 
analyses
Anti-human cell surface/cytoplasm monoclonal antibody 
(mAbs) panel labeled with distinct fluorochromes were 
used for flow cytometric immunophenotypic analysis, 
including: anti-CD3-PECy7(SK7), anti-CD4-PE(RPA-T4), 
anti-CD8-FITC(HIT8a), anti-CD69-APC(FN50), anti-CD25-
PERCP-Cy5(M-A251), anti-FoxP3-AF647(259D/C7), anti-CD19- 
FITC(HIB19), anti-CD5-PE(UCHT2), anti-CD16-FITC(3G8) 
and anti-CD56-PE(B159), all purchased from BD Bioscience, 
San Diego, CA, USA.
Haematological parameters and flow cytometric analysis 
of lymphocyte subsets
EDTA whole blood samples were employed for assessing 
haematological parameters using an automated haemato-
logical analyzer (Sysmex KX-21 N®). An additional flow 
cytometric immunophenotypic analysis was also carried 
out as follows: briefly, 50  mL aliquots of whole blood 
were incubated with 5–10  mL of fluorescent mAbs for 
30 min, at room temperature, in the dark. After incuba-
tion, the red blood cells were lysed with 2  mL of lysing 
solution (BD FACS™ Lysing Solution, BD® Biosciences 
San Diego, CA, USA) for 10 min at room temperature, in 
the dark. For FoxP3 immunostaining, cells were permea-
bilized for 10 min at room temperature, in the dark with 
2  mL of perm buffer (phosphate-buffered saline-PBS, 
0.5  % saponin, 0.5  % bovine serum albumin). After one 
wash step with PBS, stained cells were fixed in FACS fix 
solution (10 g/L of paraformaldehyde, 10.2 g/L of sodium 
cacodylate and 6.63 g/L of sodium chloride, pH 7.2). Cells 
were run in a FACSCanto II® flow cytometer (Becton–
Dickinson Company, San Jose, CA, USA) and a total of 
10,000 (100,000 for CD4/CD25/FoxP3) events collected 
for data analyses. Lymphocyte subsets were quantified 
first by specific gating strategies, using the FlowJo soft-
ware (version 9.4.1, TreeStar Inc. Ashland, OR, USA) 
as represented in Additional file  1. The results were 
expressed initially as percentage of positive cells within 
the lymphocyte gate. Absolute counts for lymphocyte 
subsets were calculated by multiplying the percentage 
of gated lymphocytes obtained by flow cytometry by the 
absolute lymphocyte count provided from the automated 
haematological analyzer.
Plasmatic cytokine quantification
The plasmatic cytokines were quantified by human Cyto-
metric Bead Array kit for IL-2, IL-4, IL-6, IL-10, TNF 
and IFN-γ, all purchased from BD Biosciences Pharmin-
gen (San Diego, CA, USA), following the instructions 
provided by the manufacturer. Data analysis was per-
formed using the FCAP ArrayTM software, V.2.0 (BD 
Biosciences, San Jose, CA, USA). Initially, the mean fluo-
rescence intensity (MFI) of each bead cluster was deter-
mined and forth logistic regression applied to build the 
standard curves. Cytokine concentrations for each sam-
ple were then extrapolated from the standard curves and 
data was expressed as pg/mL for each plasmatic cytokine.
Data mining and statistical analysis
Statistical analyses were carried out using the Graph-
Pad Prism software, version 5.0 (San Diego, CA, USA). 
Comparative analyses of continuous variables (age, hae-
matological parameters, leukocyte subsets and plasmatic 
cytokines) amongst groups (endemic controls vs pri-
mary malaria vs recurrent malaria) were performed by 
Kruskal–Wallis followed by multiple comparisons per-
formed by Dunn’s post-test.
The analysis of overall biomarker profile was per-
formed by converting the original data (leukocyte 
subsets and plasmatic cytokine profile), obtained as 
continuous variables, into categorical parameters using 
the global median cut-off calculated for the study popu-
lation. Global median values for each haematological 
parameter, lymphocyte subset and plasmatic cytokine 
were used to segregate and calculate the proportion of 
subjects with high biomarker levels (above the cut-off 
edge). The data were assembled as proposed previously 
by Luiza-Silva et al. [47] and Souza-Cruz et al. [48] and 
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the biomarker profile for endemic controls used as ref-
erence curve for comparative analyses with malaria 
patients. The χ2 test was used to compare the propor-
tions of subjects with biomarker levels above the cut-offs 
amongst groups.
Spearman’s test was used to sort variables that pro-
vided significant correlation. Linear regression analysis 
was applied to generate the best fitted line and the 95 % 
confidence interval bands.
In all cases, significance was considered at p < 0.05. Sig-
nificance level was underscored by asterisks, as follows: 
(*) if p < 0.05; (**) if p < 0.005 and (***) if p < 0.0005.
Results
Compendium of the study population, demographic 
and haematological parameters
A flowchart illustrating a compendium of the study 
population is shown in Fig. 1. Sixty-eight subjects were 
first enrolled in the present investigation due to their 
history of exposure to the malaria. Fifty-five patients 
fulfilled the inclusion criteria and were selected for the 
study, including 36 patients with primary malaria and 
19 patients with at least one recurrent malaria episode 
within 6  months after post-therapeutic monitoring 
period. Demographic and haematological parameters 
of malaria patients as well as the subjects selected as 
endemic controls (n  =  20) are presented in Table  1. 
Data analysis did not demonstrate any significant differ-
ence in the red blood cell (RBC) counts, haemoglobin 
levels and haematocrit amongst patients with malaria 
(whether primary or recurrent) and the endemic con-
trols. Both malaria groups presented lower platelet num-
bers as compared to endemic controls (p  <  0.001). The 
white blood cell (WBC) counts by multiple compari-
sons showed a reduction in both groups with malaria in 
relation to the endemic control individuals (p = 0.018). 
Malaria patients (primary and recurrent) presented 
lower lymphocyte counts as compared to endemic con-
trols (p < 0.001). Patients with primary malaria showed 
reduced monocyte counts as compared to endemic con-
trols (p =  0.014). No changes in the neutrophil counts 
were observed amongst groups (Table 1). Thrombocyto-
paenia and lymphopaenia are frequently noted in indi-
viduals with malaria [23, 51].
Low Parasitemia
< 500 parasites/mm3
n=13
High Parasitemia
> 500 parasites/mm3
n=55
Primary Malaria
n=36
Malaria Patients
n=68
Study Population
Non-infected Subjects
n=20
Endemic Controls
n=20
Recurrent Malaria 
n=19
Excluded
Fig. 1 Compendium of the study population. The study enrolled malaria patients seeking for healthcare at the Ambulatory of the Fundação de 
Medicina Tropical Dr. Heitor Vieira Dourado (FMT‑HVD), Manaus, Amazonas State, Brazil. The patient selection was performed by convenience. From 
the 68 patients participating in the initial inquiry, fifty‑five were selected and included in the study, as patients fulfilled the inclusion criteria (parasi‑
taemia was above 500 parasites/mm3). The selected patients were grouped as: primary malaria (n = 36) and recurrent malaria (n = 19) as described 
in “Methods” section. Twenty healthy individuals living in the same endemic area and with no history of malaria were invited to participate as 
endemic controls
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Biomarker profiles of primary malaria vs recurrent malaria
In order to compare the overall biomarker profiles for 
primary malaria and recurrent malaria, the continu-
ous variables obtained originally were converted into 
categorical parameters using cut-off calculated for the 
study population. The results were reported as the pro-
portion of subjects with high biomarker levels above 
the cut-offs calculated for the study population (Fig.  2). 
The biomarker profile for endemic controls was used as 
reference curve for comparative analyses with malaria 
patients. Data analysis showed a reduction in the propor-
tion of subjects with high levels of WBC as compared to 
the endemic control reference curve. It was also observed 
decreased proportion of subjects with high levels of 
monocytes particularly in patients with primary malaria 
(Fig.  2). Moreover, the proportion of subjects with high 
levels of all lymphocyte subsets was decreased in all 
malaria groups, regardless their clinical status. Analyses 
of lymphocyte subsets showed significant decrease in the 
proportion of subjects with high levels of CD4+ T-cells 
(p = 0.036) and CD8+ T-cells (p = 0.0034), particularly 
in the group of patients with recurrent malaria (Fig.  2). 
These cell subsets have a relevant role in malaria, con-
trolling the infection or associated with pathogenesis of 
severe forms of the disease, depending on their cytokine 
profiling [52].
The proportion of subjects with high levels of cytokines 
demonstrated a reversal picture characterizing a typi-
cal cytokine storm. Data analysis indicated significant 
increase in the proportion of the subjects with high 
cytokine levels in both malaria groups (Fig. 2). It was also 
noted an increased proportion of subjects with high plas-
matic IL-10 levels, selectively in patients with recurrent 
malaria (p = 0.011). This was an interesting finding, since 
IL-10 is a well-known biomarker with regulatory role 
on inflammatory processes and for being directly asso-
ciated to the protection in severe malaria [53]. Finally, 
this global analysis allowed for verifying that recurrent 
malaria is associated with a particular biomarker profile, 
characterized by decreased levels of the CD4+ and CD8+ 
T-cells along with a significant increase in the IL-10 pro-
duction (Fig. 2).
Ex vivo phenotypic features of circulating T‑cell subsets
The global analysis of categorical data has identified sig-
nificant differences in the immune response associated 
with primary and recurrent malaria. Aiming at establish-
ing useful laboratorial tools to monitor the immunologi-
cal status of patients with primary and recurrent malaria, 
the ex vivo phenotypic features of circulating T-cell sub-
sets were evaluated as continuous variables (Fig. 3). Data 
analysis confirmed that both malaria groups presented 
decreased absolute counts of CD4+ and CD8+ T-cells as 
compared to endemic controls (Fig.  3a, d). In addition, 
lower levels of CD8+ T-cells was observed in patients 
with recurrent malaria as compared to primary malaria 
(Fig. 3d). The analysis of activated T-cells demonstrated 
that both malaria groups presented significantly lower 
Table 1 Demographic and haematological parameters of the study population
Patients were grouped according to their malaria diagnosis based on microscopy data
a The patients were tested at one time point and recurrent malaria episodes recorded
b Time in months
c Data expressed as median and interquartile range (IQR25–IQR75)
d Significant differences as compared to endemic controls
* Kruskal–Wallis analyses followed by Dunn’s post-test
Endemic control (n = 20) Primary malaria (n = 36) Recurrent malaria (n = 19) p value*
Age (years), mean (SD) 27.1 (7.4) 35.4 (14.3) 39.5 (12.0) 0.005
Man/woman (%) 45/55 64/36 85/15 –
Malaria episodesa – – 3.0 (1.5–4.0) –
Last malaria attackb – – 4.0 (3.0–6.0) –
Haematological parametersc
 RBC × 103/mm3 4.8 (4.5–5.4) 4.7 (4.2–5.3) 5.0 (4.4–5.2) 0.839
 Haemoglobin (g/dL) 13.2 (12.5–14.1) 13.4 (11.5–14.4) 13.1 (12.2–14.1) 0.592
 Haematocrit (%) 43.9 (40.5–46.8) 41.9 (36.5–45.7) 42.0 (39–46.5) 0.461
 Platelets × 103/mm3 289.0 (212.5–325.2) 69.0 (37.8–100.5)d 112.0 (53–120)d <0.001
 WBC × 103/mm3 6.7 (6.1–7.8) 5.7 (4.0–7.3) 5.6 (4.7–6.8) 0.018
 Lymphocytes × 103/mm3 2.0 (1.6–2.6) 1.3 (0.7–1.8)d 1.0 (0.5–1.3)d <0.001
 Monocytes × 103/mm3 0.7 (0.5–0.8) 0.3 (0.2–0.5)d 0.5 (0.3–0.9) 0.014
 Neutrophils × 103/mm3 3.8 (3.5–5.1) 3.3 (2.1–5.1) 4.0 (3.0–4.7) 0.436
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counts of CD4+CD69+ and CD8+CD69+ as compared 
to endemic controls (Fig. 3b, e). Moreover, patients with 
recurrent malaria displayed decreased absolute counts 
and percentage of CD4+CD69+ and CD8+CD69+ as 
compared to primary malaria (Fig. 3b, c, e, f ).
Ex vivo phenotypic features of circulating NK and NKT, Treg 
and B‑cells
The ex  vivo phenotypic features of circulating NK and 
NKT, Treg and B-cells, evaluated as continuous variables, 
are presented in Additional file  2. The results showed a 
decrease in NKT, Treg, B, and B1 cells in malaria patients 
as compared to the endemic controls, with no differences 
between primary and recurrent malaria (Additional 
file 2).
Plasmatic cytokine profiles in primary malaria vs recurrent 
malaria
The categorical analysis of plasmatic cytokine indicated 
that regardless their clinical status, all malaria patients 
presented a typical cytokine storm and also pointed out 
that patients with recurrent malaria group exhibited 
enhanced proportion of subjects with high IL-10 levels 
(Fig. 2). In order to further characterize these immuno-
logical biomarkers, the plasmatic cytokine levels were 
quantified as continuous variables (Fig. 4). The data anal-
ysis demonstrated that both malaria groups have signifi-
cantly increased levels of IL-2, IL-4, IL-6, IL-10, TNF and 
IFN-γ as compared to the endemic controls. Moreover, 
the recurrent malaria group displayed significantly aug-
mented levels of IL-10, IL-6, and IL-4 as compared to 
patients with primary malaria (p < 0.0005, p < 0.005 and 
p < 0.05, respectively) (Fig. 4a–c).
Association between T‑lymphocyte subsets, plasmatic 
IL‑10 levels and number of recurrent malaria episodes
The immune response induced by recurrent malaria 
revealed significant changes in the main T-cells subsets 
and also in relevant cytokines, particularly IL-10. Intend-
ing to verify the existence of associations amongst these 
variables, correlation analysis were carried out and data 
are presented in Fig.  5. The results demonstrated a sig-
nificant positive correlation between the CD4+/CD8+ 
T-cells (ratio) and plasmatic IL-10 levels (pg/mL) selec-
tively in recurrent malaria patients (Fig. 5a–c).
To add new insights to this issue, the hypothesis as 
to whether there is any association between IL-10 lev-
els and the number of malaria episodes was then tested. 
Intergroup multiple comparisons revealed that, besides 
the higher IL-10 levels observed in all malaria subgroups 
(primary, 2–3 recurrent and >4 recurrent episodes) as 
compared to endemic controls, there was clear and pro-
gressive increase in the IL-10 levels according to the 
number of malaria episodes (Fig. 5d). Such finding rein-
forces the hypothesis of relevant role of the IL-10, par-
ticularly in recurrent malaria.
Discussion
Plasmodium vivax is highly prevalent around the world 
[1]. Regardless its former association with benign 
malaria [3, 22], complications of P. vivax malaria have 
been reported in adult patients living in Amazon Basin 
endemic areas [11, 12]. It has been proposed that a bal-
ance between the pro- and anti-inflammatory responses 
can account for the control against the development of 
the severe malaria episodes [54].
Infections with Plasmodium ssp. are capable of induc-
ing major changes in leukocyte profiling [9, 55–62]. In 
the present study, data demonstrated that patients with P. 
vivax recurrent malaria presented an unbalanced CD4+/
CD8+ T-cell ratio, which was associated with a signifi-
cant increase in the plasmatic IL-10 levels. Interestingly, 
it was verified that the IL-10 levels in patients with recur-
rent malaria were directly proportional to the number of 
malaria episodes.
In details, the ex vivo phenotypic profile of circulating 
leukocytes was characterized in patients with P. vivax 
primary and recurrent malaria. Relevant changes in 
the proportion of subjects with high levels of circulat-
ing lymphocyte subsets were found (Fig.  2). In particu-
lar, patients with recurrent malaria presented significant 
reduction of CD4+, CD8+ T-cells and activated T-cells 
(CD69-expressing CD4+and CD8+ T-cells) (Fig.  3). The 
reduction among those subpopulations was also evi-
dent in other studies carried out with P. vivax naturally 
infected individuals [55, 59, 63, 64]. Those authors inter-
preted the reduction in the lymphocyte subpopulations 
in the peripheral blood as a suppressant effect in the 
response to the P. vivax [55, 56, 63–65]. According to 
them, such reduction could be due to the high apoptosis 
(See figure on previous page) 
Fig. 2 Biomarker profiles of primary malaria vs recurrent malaria. The biomarker profiles were performed by converting the original data (leukocyte 
subsets and plasmatic cytokine profile), obtained as continuous variables, into categorical parameters. The results were reported as the proportion 
of subjects with high biomarker levels above the cut‑offs calculated for the study population, as described in “Methods” section. The data were 
arranged as descendent biomarker profile for endemic controls (white bars), and used as reference curve (dotted line) for comparative analyses with 
malaria patients (primary malaria = light-gray bars and the recurrent malaria = dark-gray bars). The χ2 test was used to identify significant differences 
at p < 0.05. Asterisks represents the significance levels (*p < 0.05, **p < 0.005 and ***p < 0.0005). Significant differences between primary and recur‑
rent malaria were represented by hash
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levels or to the relocation of the cells in the liver and in 
other lymphoid compartments [55, 64, 66–68]. In the 
present study, the major changes, occurred in T-lympho-
cyte subsets, were observed in the group with recurrent 
malaria; however, further investigations must be per-
formed to elucidate it, as the phenomenon is more accen-
tuated in this group.
Comparison of plasmatic cytokine levels showed spe-
cific characteristics suggestive of a massive cytokine 
storm in patients with primary and recurrent malaria as 
compared to healthy endemic controls (Fig. 2). In malaria 
patients, the levels of IL-6 and IL-10 were increased 
expressively in relation to other cytokines (Fig.  4), sup-
porting what was noted in other studies on non-com-
plicated malaria [69–72]. It is well established that the 
unbalance of the pro- and anti-inflammatory mediators is 
a fundamental component in the malaria pathogenesis by 
the P. vivax [9, 35, 46, 58, 64, 73–76]. In this study, levels 
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of the IL-10, IL-6 and IL-4 were higher in patients with 
recurrent malaria. Nonetheless, it could not be directly 
compared to data found in the literature due to the dif-
ferent methodology used. It must be mentioned that no 
patient participating in this study developed any compli-
cation during the acute infection. This is an important 
indication that within a short period of time, recurrent 
infections by the P. vivax did not increase the risk for 
complications, as reported previously in other studies 
[77, 78]. Probably, such risk is associated to the hyper-
reactivity of the immune system, as it is verified in Afri-
can children after recent malaria episode [79–81].
Although several studies have shown the dynamics of 
the subpopulations during P. vivax infection, the corre-
lation between such findings and the number of malaria 
episodes were less explored [9, 55–62]. The findings indi-
cate a direct association between the CD4+/CD8+ T-cells 
ratio and plasmatic IL-10 cytokine levels, selectively in 
patients with recurrent malaria (Fig.  5). Recent stud-
ies determined that after the first malaria infection, the 
T-cells secreting IL-10 are more stable and have a longer 
life span as compared to IFN-γ-producing T-cells [82–84].
Supporting these findings, the data presented here 
demonstrated that the levels of IL-10 were directly pro-
portional to the number of malaria episodes [64, 83, 84]. 
Several reports have proposed that the resistance pattern 
or susceptibility to the infection by the Plasmodium is 
related to the cytokine microenvironment, with resist-
ance to the parasite relying on cytokines such as IFN-γ, 
TNF, IL-12, and GM-CSF, while susceptibility is associ-
ated to the IL-10, IL-4 and TGF-β [43, 85].
The IL-10 plays an important effect inasmuch as it is 
capable of deactivating macrophages, and it is indirectly 
responsible by decreasing the production of the IFN-γ. In 
this way, IL-10 actuates by cushioning the potentially harm-
ful effects of the macrophage activation on the host tissue 
[86]. In this study, the high production of IL-10 was remark-
able in patients with recurrent malaria, being very low in 
patients with primary malaria. IL-10 has been indicated as 
an important regulator of the harmful immune responses to 
the host [87]. However, due to its inhibitory ability over the 
macrophagic hyperactivation, the secretion of such cytokine 
would reduce the control of the host over the circulating par-
asites, thus possibly favoring the relapse of the infection [85].
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One of the limitations of this study was the impos-
sibility to define which mechanisms are involved in the 
development of the recurrent infection, considering the 
multiple etiological factors involved in this phenomenon. 
Nevertheless, the data indicate the crucial immunoregu-
latory effect of the IL-10 in recurrent infections. It is also 
required that further investigation should be undertaken 
to shed light on the association between the decreased 
CD4+/CD8+ T-cell ratio and the increased plasmatic 
IL-10 levels during recurrent malaria. The findings sug-
gest that the gradual immunity acquisition is depend-
ent on the exposition involving a control of the immune 
response mediated by IL-10. Future prospective studies 
are required in order to assess the risk factors associated 
to the relapse of the P. vivax malaria and its relationship 
with different components of the immune response.
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Conclusion
Although this study has been conducted with a relatively 
small number of patients, our findings have shown that 
recurrent malaria, within 6 months after the end of ther-
apeutic monitoring period, induces a relevant IL-10-me-
diated response, suggesting the occurrence of a gradual 
acquisition of modulatory immunity. The present study is 
a descriptive investigation and does not report the mech-
anisms underlying the development of distinct patterns 
of immune response in patients with recurrent malaria. 
The hypothesis that IL-10 would have a protective role 
against complications of recurrent malaria still requires 
further investigation. It is important to keep in mind that, 
due to its modulatory activity, the high levels of the IL-10 
would also favor the occurrence of recrudescence/relapse 
of P. vivax malaria.
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